D-/L-isothymidine incorporation in core sequence of aptamer BC15 enhanced its binding affinity to hnRNP A1 protein

Electronic Supplementary Information

Liyu Li^{†,a}, Xiantao Yang^{†,a,c}, Kunfeng Li^a, Guangpu Zhang^a, Yuan Ma^a, Baobin Cai^a, Shaohua Li^b, Hongmei Ding^b, Jiali Deng^a, Xiyan Nan^a, Jing Sun^a, Yun Wu^a, Ningsheng Shao^b, Lihe Zhang^a and Zhenjun Yang^{*,a}

a. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Beijing 100191, China.

b. Department of Biochemistry and Molecular Biology, Beijing Institute of Basic Medical Sciences, Beijing, China.

c. School of Pharmacy, Chengdu Medical College, 783 Xindu Avenue, Xindu District, Chengdu 610500, China. † These authors contributed equally to this paper.

^{*} To whom correspondence should be addressed. Tel. & Fax: +86-10-82802503. E-mail: yangzj@bjmu.edu.cn.

Content

Figure S1. HPLC separation of BC15-31 and the variants (BC15-31 as example, the trace shown here is representative for the purification of all variants of the parent oligonucleotide, regardless of the number and location of the isoT residues in each case). Dionex UltiMate 3000 HPLC, XBridgeTM OST C18 column (2.5 μ m, 10 mm × 50 mm), gradient program: 15-35% eluent A in 35 min (A: CH₃CN; B: 0.1 M Et₃N-CH₃COOH in water, pH = 7.7), column temperature 40 °C, flow rate 1.5 mL/min.

Figure S2. Purity identification of BC15-31 and the variants by analytical HPLC (Since all oligos had similar traces upon their initial purification (Figure S1) and the analogous oligo peak were collected in all cases, the post-purification assay data are expected to be very similar for all oligos, parent BC15-31 oligo and 4 randomly selected variants were assayed to representatively verify the purity. Trace a: parent BC15-31, trace b: BC15-31-3_L, trace c: BC15-31-26_D, trace d: BC15-31-3_L30_D, trace e: BC15-31-3_D15_D). Agilent 1200 HPLC, XBridgeTM OST C18 column (2.5 μ m, 10 mm × 50 mm), gradient program: 0-25% eluent A in 35 min (A: CH₃CN; B: 0.1 M Et₃N-CH₃COOH in water, pH = 7.7), column temperature 25 °C, flow rate 1.5 mL/min.

Figure S3. MALDI-TOF-MS of BC15-31 and its variants.

Figure S4. Surface plasmon resonance of BC15 (A) and BC15-31 (B) and BC15-27 (C) and NC (D) with hnRNP A1. DNA sequences are given in the section of 'Materials and Methods'. The concentrations of protein were 5, 10, 50, 100, 200, 500, 1000nM, respectively. The data were fitted in a Langmuir Binding (1:1) model.

Figure S5. ELISA results of mismatched BC15-31variants and hnRNP A1.

Figure S6. Characterization of Bis-D-/L-isoT-modified BC15-31 combine with hepatocarcinoma slides by fluorescent inverted microscope imaging ($10\times$). BC15-31 and blank as control. Hepatocarcinoma slides were incubated with FAM-labeled different aptamers. Basal brightness of three groups is different because of the various hepatocarcinoma slides thickness. Bar = 100 µm.

Table S1. Mass spectrometry analysis results of the potential protein targets of BC15-31 (A) and BC15 lane (B)

Table S2. Sequences of mismatched BC15-31 variants.

 Table S3. BC15-31 and D/L-isoT modified variants.



Figure S1. HPLC separation of BC15-31 and the variants (BC15-31 as example, the trace shown here is representative for the purification of all variants of the parent oligonucleotide, regardless of the number and location of the isoT residues in each case). Dionex UltiMate 3000 HPLC, XBridgeTM OST C18 column (2.5 μ m, 10 mm × 50 mm), gradient program: 15-35% eluent A in 35 min (A: CH₃CN; B: 0.1 M Et₃N-CH₃COOH in water, pH = 7.7), column temperature 40 °C, flow rate 1.5 mL/min.



Figure S2. Purity identification of BC15-31 and the variants by analytical HPLC (Since all oligos had similar traces upon their initial purification (Figure S1) and the analogous oligo peak were collected in all cases, the post-purification assay data are expected to be very similar for all oligos, parent BC15-31 oligo and 4 randomly selected variants were assayed to representatively verify the purity. Trace a: parent BC15-31, trace b: BC15-31-3_L, trace c: BC15-31-26_D, trace d: BC15-31-3_L30_D, trace e: BC15-31-3_D15_D). Agilent 1200 HPLC, XBridgeTM OST C18 column (2.5 µm, 10 mm × 50 mm), gradient program: 0-25% eluent A in 35 min (A: CH₃CN; B: 0.1 M Et₃N-CH₃COOH in water, pH = 7.7), column temperature 25 °C, flow rate 1.5 mL/min.





BC15-31, Found: 9766; Calcd: 9765.



BC15-31-3L, Found: 9766; Calcd: 9765.



BC15-31-3D, Found: 9766; Calcd: 9765.



BC15-31-3L/30L, Found: 9766; Calcd: 9765.

BC15-31-1L/30L, Found: 9766; Calcd: 9765.

The second s



Fam-BC15-31, Found: 10297; Calcd: 10302.



Fam-BC15-31-1L/30L, Found: 10303; Calcd: 10302.



Fam-BC15-31-1L/3L, Found: 10303; Calcd: 10302.



Fam-BC15-31-3L/30L, Found: 10303; Calcd: 10302.



Fam-BC15-31-3D/30D, Found: 10302; Calcd: 10302.



Fam-BC15-31-3L/30D, Found: 10299; Calcd: 10302.



Figure S4. Surface plasmon resonance of BC15 (A) and BC15-31(B) and BC15-27(C) and NC(D) with hnRNP A1.



Figure S5. ELISA results of mismatched BC15-31variants and hnRNP A1.



Figure S6. Characterization of Bis-D-/L-IsoT-modified BC15-31 combine with hepatocarcinoma slides by fluorescent inverted microscope imaging $(10\times)$. BC15-31 and blank as control.

 Table S1. Mass spectrometry analysis results of the potential protein targets of BC15-31 (A) and BC15

 lane (B)

Α

Accession	Description	Score
F8W6I7	Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens GN=HNRNPA1 PE=2	1053
	SV=2 - [F8W6I7_HUMAN]	
P22626	Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens GN=HNRNPA2B1	833
	PE=1 SV=2 - [ROA2_HUMAN]	
Q15717	ELAV-like protein 1 OS=Homo sapiens GN=ELAVL1 PE=1 SV=2 - [ELAV1_HUMAN]	146
Q13151	Heterogeneous nuclear ribonucleoprotein A0 OS=Homo sapiens GN=HNRNPA0 PE=1	123
	SV=1 - [ROA0_HUMAN]	
Q02878	60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 PE=1 SV=3 - [RL6_HUMAN]	107

В

Accession	Description	Score
F8W6I7	Heterogeneous nuclear ribonucleoprotein A1 OS=Homo sapiens GN=HNRNPA1 PE=2	961
	SV=2 - [F8W6I7_HUMAN]	
P22626	Heterogeneous nuclear ribonucleoproteins A2/B1 OS=Homo sapiens GN=HNRNPA2B1	920
	PE=1 SV=2 - [ROA2_HUMAN]	
Q15717	ELAV-like protein 1 OS=Homo sapiens GN=ELAVL1 PE=1 SV=2 - [ELAV1_HUMAN]	137
Q02878	60S ribosomal protein L6 OS=Homo sapiens GN=RPL6 PE=1 SV=3 - [RL6_HUMAN]	124
Q13151	Heterogeneous nuclear ribonucleoprotein A0 OS=Homo sapiens GN=HNRNPA0 PE=1	121
	SV=1 - [ROA0_HUMAN]	
P04264	Keratin, type II cytoskeletal 1 OS=Homo sapiens GN=KRT1 PE=1 SV=6 - [K2C1_HUMAN]	106

Table S2. Sequences of mismatched BC15-31 variants

Name	Sequence
BC15-31mm1	5'-TCT CCC CACCTA CCT CCC CTC TCT CTC TAT C-3'
BC15-31mm2	5'-TGT GGC GAG GTA GGT CCC CTG TGT GTG TATC-3'
BC15-31mm3	5'-TGT CCC GAG GTA GGT GGG GTG TGT GTG TATC-3'
BC15-31mm4	5'-TGT GGC GAG GTA GGT GGG GTC TCT CTC TATC-3'
BC15-31mm5	5'-TGT GGC GAG GTA GGT GGG GAG AGA GAG TATC-3'
BC15-31mm6	5'-TGT GGC GAG GTA GGT GGG G <mark>AC ACA CAC</mark> TATC-3'

Name	Sequence(5 ² -3 ²)	MALDI-TOF-MS	
Ivanie		Calcd.	Found
BC15-31	5'-TGTGGCGAGGTAGGTGGGGTGTGTGTGTATC-3'	9765	9766
BC15-31-3L	5'-TGTLGGCGAGGTAGGTGGGGTGTGTGTGTATC-3'	9765	9766
BC15-31-3D	5'-TGTDGGCGAGGTAGGTGGGGTGTGTGTGTATC-3'	9765	9766
BC15-31-15L	5'-TGTGGCGAGGTAGGTLGGGGTGTGTGTGTGTATC-3'	9765	9766
BC15-31-15D	5'-TGTGGCGAGGTAGGT _D GGGGTGTGTGTGTATC-3'	9765	9766
BC15-31-22L	5'-TGTGGCGAGGTAGGTGGGGTGTLGTGTGTATC-3'	9765	9766
BC15-31-22D	5'-TGTGGCGAGGTAGGTGGGGTGT _D GTGTGTATC-3'	9765	9766
BC15-31-24L	5'-TGTGGCGAGGTAGGTGGGGTGTGTLGTGTATC-3'	9765	9766
BC15-31-24D	5'-TGTGGCGAGGTAGGTGGGGTGTGT _D GTGTATC-3'	9765	9766
BC15-31-26L	5'-TGTGGCGAGGTAGGTGGGGTGTGTGT <mark>L</mark> GTATC-3'	9765	9766
BC15-31-26D	5'-TGTGGCGAGGTAGGTGGGGTGTGTGT <mark>D</mark> GTATC-3'	9765	9766
BC15-31-28L	5'-TGTGGCGAGGTAGGTGGGGTGTGTGTGT <mark>L</mark> ATC-3'	9765	9766
BC15-31-30L	5'-TGTGGCGAGGTAGGTGGGGTGTGTGTGTAT _L C-3'	9765	9766
BC15-31-30D	5'-TGTGGCGAGGTAGGTGGGGTGTGTGTGTAT _D C-3'	9765	9766
BC15-31-3L/30L	5'-TGTLGGC GAG GTA GGT GGG GTG TGT GTG TATLC-3'	9765	9766
BC15-31-1L/30L	$5'$ - T_L GT GGC GAG GTA GGT GGG GTG TGT GTG TA T_L C- $3'$	9765	9766
BC15-31-1L/3L	5'- T_LGT_LGGC GAG GTA GGT GGG GTG TGT GTG TATC-3'	9765	9766
BC15-31-3L/30D	5'-TGT _L GGC GAG GTA GGT GGG GTG TGT GTG TAT _D C-3'	9765	9766
BC15-31-3D/30D	5'-TG T _D GGC GAG GTA GGT GGG GTG TGT GTG TA T _D C-3'	9765	9766
BC15-31-15D/30D	5'-TGTGGC GAG GTA GGT _D GGG GTG TGT GTG TAT _D C-3'	9765	9766
BC15-31-3L/15D	5'-TG T_LGGC GAG GTA GGT_D GGG GTG TGT GTGTATC-3'	9765	9766
BC15-31-3D/15D	5'-TGT _D GGC GAG GTA GGT _D GGG GTG TGT GTG TATC-3'	9765	9766

Table S3. BC15-31 and D/L-isoT modified variants